Rohit Loomba, MD, is tenured professor of Medicine, Director of Hepatology, at University of California at San Diego. He is an internationally recognized thought leader in translational research and innovative clinical trial design in NASH and non-invasive assessment of NAFLD.

Dr. Loomba is the founding director of the UCSD NAFLD Research Center where his team is conducting research in non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging end-points, and integrated OMICs using microbiome, metabolome and lipidome. This integrated approach has led to establishment of MRI-PDFF as a non-invasive biomarker of treatment response in early phase trials in NASH, which has now been adopted in 25 global clinical trials. He has conducted seminal trials such as the MOZART Trial being the first trial in NASH with comprehensive MRI as well as 2D and 3D MRE assessment paired with liver biopsies in NASH.

His research is funded by the NIH, AGA, NSF and industry. He is the Principal Investigator for adult hepatology for the NIDDK-sponsored NASH Clinical Research Network and serves as Chair of the NAFLD Special Interest Group of the AASLD.

Dr. Loomba has published more than 290 manuscripts and has an H-index of 68. He serves on the Editorial Board of Gastroenterology, Journal of Hepatology, GUT and Nature Reviews in Gastroenterology and Hepatology. He is the Deputy Editor of HEPATOLOGY, the official journal of the AASLD.

‍